Annexon, Inc.
General ticker "ANNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $432.8M (TTM average)
Annexon, Inc. follows the US Stock Market performance with the rate: 24.5%.
Estimated limits based on current volatility of 5.0%: low 4.09$, high 4.45$
Factors to consider:
- Total employees count: 100 (+40.8%) as of 2024
- Top business risk factors: Limited operating history, Product liability, Labor/talent shortage/retention, Economic downturns and volatility, Supply chain disruptions
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.33$, 8.45$]
- 2025-12-31 to 2026-12-31 estimated range: [2.66$, 7.00$]
Financial Metrics affecting the ANNX estimates:
- Positive: with PPE of -5.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.58 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 83.73 > 63.39
- Positive: Inventory ratio change, % of 0 <= 0
Short-term ANNX quotes
Long-term ANNX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $145.60MM | $143.72MM | $154.07MM |
| Operating Income | $-145.60MM | $-143.72MM | $-154.07MM |
| Non-Operating Income | $3.65MM | $9.49MM | $15.87MM |
| R&D Expense | $112.50MM | $113.76MM | $119.45MM |
| Income(Loss) | $-141.95MM | $-134.24MM | $-138.20MM |
| Profit(Loss)* | $-141.95MM | $-134.24MM | $-138.20MM |
| Stockholders Equity | $231.19MM | $250.56MM | $293.11MM |
| Assets | $285.10MM | $297.67MM | $350.07MM |
| Operating Cash Flow | $-116.31MM | $-121.14MM | $-118.01MM |
| Capital expenditure | $6.53MM | $0.19MM | $0.01MM |
| Investing Cash Flow | $58.44MM | $70.70MM | $-218.80MM |
| Financing Cash Flow | $122.91MM | $135.52MM | $161.21MM |
| Earnings Per Share** | $-2.60 | $-1.77 | $-1.01 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.